The tariff classification and country of origin of Calcitonin Salmon Injection, USP in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredient Calcitonin Salmon (made in Spain) with the inactive ingredients into the final dosage Calcitonin Salmon Injection, USP in India does not result in a substantial transformation and the country of origin will be Spain.
Ruling text
In your letter dated December 22, 2025, you requested a tariff classification and country of origin determination ruling. Calcitonin Salmon Injection, imported in 400 USP Units/2 mL vials, is a synthetic polypeptide hormone that acts as a calcitonin receptor agonist. It is indicated for the treatment of Paget’s disease, hypercalcemia, and postmenopausal osteoporosis.
The applicable subheading for the Salmon Calcitonin Injection, USP in dosage form will be 3004.39.0050, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other, containing hormones or other products of heading 2937: Other: Other.” The general rate of duty will be free. You also requested a country of origin determination.
You stated that the active pharmaceutical ingredient (API), Calcitonin Salmon is manufactured in Spain and that the finished Calcitonin Salmon Injection in dosage form is made in India. In India, the Calcitonin Salmon will be mixed with various inactive ingredients to produce the final Calcitonin Salmon Injection in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
In this case, we find the mixing of the active ingredient Calcitonin Salmon (made in Spain) with the inactive ingredients into the final dosage Calcitonin Salmon Injection, USP in India does not result in a substantial transformation and the country of origin will be Spain. The duties cited above are current as of this ruling’s issuance. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/.
This ruling does not address the applicability of any additional duties, taxes, fees, exactions and/or other charges, which may apply to the goods discussed herein. This includes, but is not limited to, tariffs and other duties as provided for in Subchapter III to Chapter 99, HTSUS.
Thus, for example, in addition to the classification stated above, the merchandise covered by this ruling may also need to be reported with either the Chapter 99 provision under which an additional tariff applies or one of the Chapter 99 provisions covering exceptions to such tariffs.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N357260).